期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

激素非依赖性前列腺癌分子机制的研究现状 被引量：4

Current Situation of Researches on the Molecule Mechanism of Hormone Refractory Prostate Cancer
下载PDF
导出
摘要 前列腺癌大多在抗雄激素治疗12～18个月后转变为激素非依赖性，本文重点从生物学角度阐述了雄激素受体及其基因突变、细胞凋亡、p53基因、p21基因和EphB2基因对前列腺癌的影响，对前列腺癌的基础研究有一定的指导作用。 Most cases of prostate cancer become hormone refractory after 12 to 18 months of androgen deprivation therapy. The etiology of the disease is thought to be muhifactorial, associated with genetic, dietary, and environmental factors. The article reviews the current situation of researches at home and abroad on the molecule mechanism of hormone refractory. It expounds the influence of the androgen receptor and its genetic mutation, apoptosis and the gene changes of p53, p21, EphB2 on prostate cancer. It is hoped to be of some directive value for the studies of prostate cancer.
作者 杨念钦 王益鑫
机构地区 上海第二医科大学附属仁济医院泌尿外科上海市男科学研究所
出处 《中华男科学杂志》 CAS CSCD 2006年第6期551-554,共4页 National Journal of Andrology
关键词 前列腺肿瘤 发病机制 prostate cancer mechanism
分类号 R737.25 [医药卫生—肿瘤]
  • 相关文献

参考文献21

  • 1JemalA ThomasA MurrayT etal.Cancer statistics,2002[J].CA Cancer J Clin,2002,52(1):23-47.
  • 2Small EJ,Harris KA.Secondary hormonal manipulation of prostate cancer[J].Semin Urol Oncol,2002,20(3 Suppl 1):24-30.
  • 3Fizazi K,Martinez LA,Sikes CR,et al.The association of p21(WAF-l/CIPI)with progression to androgen-independent prostate cancer[J].Clin Cancer Res,2002,8(3):775-781.
  • 4Labrie F.Endocrine therapy for prostate cancer[J].Endocrinol Metab Clin North Am,1991,20(4):845-872.
  • 5Abrahamasson PA.Neuroendocrine cells in tumour growth of the prostate[J].Endocr Relat Cancer,1999,6(4):503-519.
  • 6Heinlein CA,Chang C.Androgen receptor in prostate cancer[J].Endocr Rev,2004,25(2):276-308.
  • 7Powell SM,Christiaens V,Voulgaraki D,et al.Mechanism of androgen receptor signalling via steroid receptor coactivator-l in prostate[J].Endocr Relat Cancer,2004,11(1):117-130.
  • 8Crocitto LE,Hendeson BE,Coetezee GA,et al.ldentification of two germline point mutation in the 5' UTR of the androgen receptor gene in men with prostate cancer[J].J Urol,1997,158(4):1599-1601.
  • 9Prins GS.Molecular biology of the androgen receptor[J].Mayo Clin Proc,2000,75(Suppl):S32-S35.
  • 10Brinkmann AO,TraPman J.Prostate cancer schemes for androgen escape[J].Nat Med,2000,6(6):628-629.

二级参考文献10

  • 1Pisters LL, Pettaway CA, Troncoso P, et al. Evidence that transfer of functional P53 protein results in increased apoptosis in prostate cancer [J]. Clin Cancer Res,2004,10 ( 8 ): 2587 -2593.
  • 2Shenk JL, Fisher CJ, Chen SY, et al. p53 represses androgeninduced transactivation of prostate specific antigen by disrupting hAR amino-to carboxyl-terminal interaction [J]. J Biol Chem,2001, 276(42): 38472-38479.
  • 3Quinn DI, Henshall SM, Head DR, et al. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy [J]. Cancer Res, 2000, 60(6) :1585-1594.
  • 4Ko SC, Gotoh A, Thalmann GN, et al. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastic human prostate cancer model [J]. Hum Gene Ther, 1996, 7(14) :1683-1691.
  • 5Shurbaji MS, Kalbfleisch JH, Thurmond TS. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer[J]. Hum Pathol, 1995, 26( 1 ) :106-109.
  • 6Apakama I, Robinson MC, Walter NM, et al. bcl-2 over expression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer[J]. Br J Cancer, 1996, 74 ( 8 ):1258-1262.
  • 7Johnson MI, Robinson MC, Marsh C, et al. Expression of Bcl2, Bax, and p53 in high-grade prostate intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation [J]. Prostate, 1998, 37(4) :223-229.
  • 8Oxley JD, Winkler MH, Parry K, et al. p53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy[J]. BJU Int, 2002, 89( 1 ) :27-32.
  • 9Nesslinger NJ, Shi XB, de Vere White RW. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53 [J]. Cancer Res, 2003, 63 ( 9 ):2228-2233.
  • 10Rege YD, Rangnekar VM. Molecular therapy intervention prospects in prostate cancer[J]. Curr Pharm Des,2004, 10(5):523-530.

共引文献10

同被引文献74

引证文献4

二级引证文献19

中华男科学杂志
2006年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部